Farge D, Frere C, Connors JM, Khorana A, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Use of anti-factor Xa levels in cancer patients taking direct oral anticoagulants. In: ISTH Congr. Abstr. https://abstracts.isth.org/abstract/use-of-anti-factor-xa-levels-in-cancer-patients-taking-direct-oral-anticoagulants/. Accessed 24 Feb 2023

Delavenne X, Mismetti P, Basset T (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal 78–79:150–153

Article  PubMed  Google Scholar 

Mavri A, Vene N, Božič-Mijovski M, Miklic M, Soderblom L, Pohanka A et al (2021) Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation. Sci Rep 11:13908

Article  CAS  PubMed  PubMed Central  Google Scholar 

Velev M, Puszkiel A, Blanchet B, De Percin S, Delanoy N, Medioni J et al (2021) Association between olaparib exposure and early toxicity in BRCA-mutated ovarian cancer patients: results from a retrospective multicenter study. Pharm Basel Switz 14:804

CAS  Google Scholar 

https://cancer-druginteractions.org/checker

Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M (2019) Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations. Clin Pharmacol Ther 105:229–241

Article  CAS  PubMed  Google Scholar 

Deng F, Sistonen J, Neuvonen M, Niemi M (2023) Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors. Basic Clin Pharmacol Toxicol 133:428–436

Article  PubMed  Google Scholar 

Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58:1265–1279

Article  PubMed  PubMed Central  Google Scholar 

Lafaie L, Hodin S, Saïb S, Bin S, Bertoletti L, Delavenne X et al (2022) Tyrosine kinase inhibitors and direct oral anticoagulants: in vitro evaluation of drug-drug interaction mediated by P-glycoprotein. Fundam Clin Pharmacol 36:860–868

Article  CAS  PubMed  Google Scholar 

Hanigan S, Das J, Pogue K, Barnes G, Dorsch M (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 49:636–643

Article  CAS  PubMed  Google Scholar 

Limcharoen S, Pongchaidecha M, Pimsi P, Limprasert S, Suphanklang J, Santimaleeworagun W et al (2022) Do apixaban plasma levels relate to bleeding? The clinical outcomes and predictive factors for bleeding in patients with non-valvular atrial fibrillation. Biomedicines 10:2001

Article  CAS  PubMed  PubMed Central  Google Scholar